MICHAEL VAUGHN: Open Payments
NPI 1598889420 · DECATUR, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$980 in 50 payments from 13 companies in 2025. Trend: 2023 $1,466 · 2024 $1,003 · 2025 $980
Food & beverage: $878Education: $101
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $183 |
| Otsuka America Pharmaceutical, Inc. | 8 | $164 |
| Lundbeck LLC | 7 | $152 |
| Teva Pharmaceuticals USA, Inc. | 5 | $152 |
| Axsome Therapeutics, Inc. | 4 | $67 |
| ABBVIE INC. | 3 | $55 |
| Janssen Pharmaceuticals, Inc | 2 | $50 |
| Neurocrine BioSciences, Inc. | 2 | $45 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| Alkermes, Inc. | 1 | $27 |
Products named: ABILIFY ASIMTUFII, TRINTELLIX, REXULTI, Auvelity, VRAYLAR, AUSTEDO XR, INGREZZA, Qelbree.
Industry payments across GA — which companies pay providers there.
